Replimune Group Inc logo


Replimune Group Inc


Earnings Summary

Net Profits


Net Profits:

Replimune Group Inc’s net profit fell -54.71% since last year same period to $-42.25Mn in the Q2 2022. On a quarterly growth basis, Replimune Group Inc has generated -33.31% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Replimune Group Inc post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

Replimune Group Inc’s earning per share (EPS) estimates for the current quarter stand at -0.64 - a -10.34% fall from last quarter’s estimates.

EPS Estimate Current Year:

Replimune Group Inc’s earning per share (EPS) estimates for the current year stand at -0.64.

Key Ratios

Key ratios of the Replimune Group Inc post its Q2 2022 earnings

Return on Assets (ROA)
Return on Equity (ROE)
Dividend Per Share (DPS)


Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Replimune Group Inc’s return on assets (ROA) stands at -0.16.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Replimune Group Inc’s return on equity (ROE) stands at -0.3.

Dividend Per Share (DPS):

Replimune Group Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune's Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications.

Replimune Group Inc
Woburn, Massachusetts, United States
Health Technology
philip Astley-Sparke